Literature DB >> 19421879

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation.

Ronald R Gomes1, Patricia Buttke, Emmanuel M Paul, Robert A Sikes.   

Abstract

Spontaneous development of osteoblastic lesions of prostate cancer (PCa) in mice is modeled by orthotopic (intraprostatic) deposition of neoplastic cells followed by an extremely long latency associated with low incidence of spontaneous bone metastasis. Intracardial injection results in overt bone metastases only with osteoclastic PCa cells (i.e., PC-3). Herein, we report that androgen independent osteoblastic PCa cells readily colonize bone when in a high remodeling state. SCID/Beige mice were subjected to periods of intermittent human parathyroid hormone 1-34 (hPTH) exposure, followed by an intracardiac infusion of osteoblastic C4-2 PCa cells. At the time of PCa infusion, analysis of bone turnover markers from mice treated with hPTH revealed significant increases in osteocalcin (55.06 +/- 7.5 vs. 74.01 +/- 18.5 ng/ml) and TRAcP-5b (3.3 +/- 0.6 vs. 4.81 +/- 0.8 U/l), but no change in type I collagen C-terminal teleopeptide levels relative to control mice. Analysis of femoral cancellous bone architecture revealed significant increases in bone mineral density, trabecular thickness (0.056 +/- 0.002 vs. 0.062 +/- 0.001 mm) and porosity, but significant decreases in connectivity density and trabecular number in hPTH treated mice relative to controls. By 8 weeks post-infusion, 70% of mice pre-treated with hPTH demonstrated detectable serum prostate specific antigen (PSAs) ranging between 2 and 18.8 ng/ml. Immuno-histochemical labeling of femurs for PSA and pan-Cytokeratin revealed the presence of significant tumor cell nests in marrow and trabecular spaces. These results suggest that: (1) local bone physiology is an important factor for developing osteoblastic/sclerotic PCa bone metastases in murine hosts; (2) the establishment of osteosclerotic PCa bone metastases in mice is enhanced by alterations that drive bone formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19421879     DOI: 10.1007/s10585-009-9263-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  48 in total

1.  Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer.

Authors:  N Buchs; J P Bonjour; R Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

2.  Distribution of IGFBP-rP1 in normal human tissues.

Authors:  A Degeorges; F Wang; H F Frierson; A Seth; R A Sikes
Journal:  J Histochem Cytochem       Date:  2000-06       Impact factor: 2.479

Review 3.  Skeletal metastases in advanced prostate cancer: cell biology and therapy.

Authors:  M Koutsilieris
Journal:  Crit Rev Oncol Hematol       Date:  1995-01       Impact factor: 6.312

4.  Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study.

Authors:  H Rico; A Uson; E R Hernandez; P Prados; P Paramo; J A Cabranes
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

Review 5.  Structural substrates of bone marrow function.

Authors:  P P De Bruyn
Journal:  Semin Hematol       Date:  1981-07       Impact factor: 3.851

6.  Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds.

Authors:  W D Yang; R R Gomes; M Alicknavitch; M C Farach-Carson; D D Carson
Journal:  Tissue Eng       Date:  2005 Jan-Feb

7.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

8.  Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.

Authors:  R Podbesek; C Edouard; P J Meunier; J A Parsons; J Reeve; R W Stevenson; J M Zanelli
Journal:  Endocrinology       Date:  1983-03       Impact factor: 4.736

Review 9.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Bruce E LeRoy; Stefanie Mandl; Christopher H Contag
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

10.  Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.

Authors:  M Koutsilieris; G Tolis
Journal:  Prostate       Date:  1985       Impact factor: 4.104

View more
  9 in total

1.  Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals.

Authors:  Christopher P Geffre; Erika Pond; Gerald D Pond; Isis C Sroka; Jaime M Gard; Bethany A Skovan; William E Meek; Terry H Landowski; Raymond B Nagle; Anne E Cress
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Optimal management of bone metastases in prostate cancer.

Authors:  Raid Aljumaily; Paul Mathew
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

3.  Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.

Authors:  Chu Zhang; Mehrnoosh Soori; Fayth L Miles; Robert A Sikes; Daniel D Carson; Leland W K Chung; Mary C Farach-Carson
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

4.  Platelets govern pre-metastatic tumor communication to bone.

Authors:  B A Kerr; N P McCabe; W Feng; T V Byzova
Journal:  Oncogene       Date:  2013-09-15       Impact factor: 9.867

Review 5.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

6.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

7.  Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.

Authors:  M Tezval; G Serferaz; T Rack; L Kolios; S Sehmisch; U Schmelz; H Tezval; K M Stuermer; E K Stuermer
Journal:  World J Urol       Date:  2011-02-05       Impact factor: 4.226

Review 8.  Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.

Authors:  Tilman Todenhöfer; Arnulf Stenzl; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Endocrinol       Date:  2015-01-31       Impact factor: 3.257

9.  Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma.

Authors:  Pankaj Mathur; Daisy Alapat; Manoj Kumar; Sharmilan Thanendrarajan
Journal:  Clin Case Rep       Date:  2017-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.